Results 91 to 100 of about 234,058 (316)

Characterization and Potential Applications of Dog Natural Killer Cells in Cancer Immunotherapy. [PDF]

, 2019
Natural killer (NK) cells of the innate immune system are a key focus of research within the field of immuno-oncology based on their ability to recognize and eliminate malignant cells without prior sensitization or priming.
Canter, Robert J, Gingrich, Alicia A, Modiano, Jaime F   +2 more
core   +2 more sources

A Dual Immunotherapy Nanoparticle Improves T‐Cell Activation and Cancer Immunotherapy

Advanced Materials, 2018
AbstractCombination immunotherapy has recently emerged as a powerful cancer treatment strategy. A promising treatment approach utilizes coadministration of antagonistic antibodies to block checkpoint inhibitor receptors, such as antiprogrammed cell death‐1 (aPD1), alongside agonistic antibodies to activate costimulatory receptors, such as antitumor ...
Yu Mi, Christof C. Smith, Feifei Yang, Yanfei Qi, Kyle C. Roche, Jonathan S. Serody, Benjamin G. Vincent, Andrew Z. Wang   +7 more
openaire   +3 more sources

Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer

Molecular Oncology, EarlyView.
Dysregulation of the Hippo pathway drives nuclear accumulation of YAP/TAZ, activating stemness‐related transcriptional programs that sustain breast cancer stemness and fuel therapeutic resistance across subtypes, underscoring Hippo signaling as a targetable vulnerability. Figure created and edited with BioRender.com.
Giulia Schiavoni, Antonella Palmese, Stefano Scalera, Laura Cipriani, Davide Mascolo, Patrizia Vici, Teresa Arcuri, Lorena Filomeno, Eriseld Krasniqi, Giovanni Blandino, Giulia Bon, Marcello Maugeri‐Saccà   +11 more
wiley   +1 more source

Regimens combining radiation and immunotherapy for cancer: latest updates from 2024 ASCO Annual Meeting

Journal of Hematology & Oncology
Combination of immunotherapy with radiotherapy is under active investigation. The PACIFIC trial firmly established the treatment paradigm of consolidation immunotherapy following definitive chemoradiotherapy, inspiring a series of similar or exploratory ...
Di Liu, Leilei Wu, Xiaoling Xu, Shuangyan Yang, Ming Liu, Min Hu, Shengxiang Ren, Yaping Xu   +7 more
doaj   +1 more source

How can we increase the value of clinical trials with immunotherapy?

Journal for ImmunoTherapy of Cancer
In the 40 years since the initial studies with interleukin-2 led to the Society for Immunotherapy of Cancer’s creation, immunotherapy has become a crucial pillar of cancer therapy that is extending and improving countless lives worldwide.
David F McDermott, Michael B Atkins
doaj   +1 more source

Dendritic-Cell (DC)-Based Immunotherapy: Tumor Endothelial Marker 8 (TEM8) Gene Expression of DC Vaccines Correlates with Clinical Outcome [PDF]

, 2008
\ud Previous studies have shown that tumor-endothelial markers (TEMs) are upregulated in immunosuppressive, pro-angiogenic dendritic cells (DCs) found in tumor microenvironments. \ud We reported that pro-angiogenic monocyte-derived DCs (Mo-DCs), utilized
Bolli, Elisabetta, Ridolfi, R., Venanzi, F.M.   +2 more
core  

Targeting Oncogenic BRAF: Past, Present, and Future. [PDF]

, 2019
Identifying recurrent somatic genetic alterations of, and dependency on, the kinase BRAF has enabled a "precision medicine" paradigm to diagnose and treat BRAF-driven tumors.
Bivona, Trever G, Wu, Wei, Zaman, Aubhishek   +2 more
core   +1 more source

CCDC80 suppresses high‐grade serous ovarian cancer migration via negative regulation of B7‐H3

Molecular Oncology, EarlyView.
PAX8 is a lineage‐specific master regulator of transcription in high‐grade serous ovarian cancer (HGSC) progression. We show for the first time that PAX8 facilitates proliferation and metastasis by repressing the cell autonomous tumor suppressor CCDC80 and inducing B7‐H3 expression.
Aya Saleh, Nitzan Medina‐Itzhaki, Milena Chekov, Eden Gal‐Swisa, Roba Gabesh‐Wahabi, Inbar Savyon, Inna Naroditsky, Hilary A. Kenny, Basem Fares, Lina Korsensky, Einav Girsh, Liron Berger, Ruth Perets   +12 more
wiley   +1 more source

Integration of active ingredients from traditional Chinese medicine with nano-delivery systems for tumor immunotherapy

Journal of Nanobiotechnology
Tumor immune escape presents a significant challenge in cancer treatment, characterized by the upregulation of immune inhibitory molecules and dysfunction of immune cells. Tumor immunotherapy seeks to restore normal anti-tumor immune responses to control
Hao Zheng, Yiquan Chen, Wei Luo, Shiqi Han, Mengjuan Sun, Min Lin, Chenghan Wu, Lili Gao, Tian Xie, Na Kong   +9 more
doaj   +1 more source

Study protocol for THINK : a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types [PDF]

, 2017
Introduction: NKR-2 are autologous T cells genetically modified to express a chimeric antigen receptor (CAR) comprising a fusion of the natural killer group 2D (NKG2D) receptor with the CD3 zeta signalling domain, which associates with the adaptor ...
Aftimos, Philippe, Awada, Ahmad, Brayer, Jason B, Catala, Gaetan, Davila, Marco L, Gilham, David E, Hendlisz, Alain, Kerre, Tessa, Lehmann, Frederic F, Lonez, Caroline, Machiels, Jean-Pascal H, Odunsi, Kunle, Piette, Fanny, Sallman, David A, Van den Neste, Eric, Verma, Bikash   +15 more
core   +1 more source